|
【结 构 式】 
|
【分子编号】28390 【品名】(3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-oxime 【CA登记号】 |
【 分 子 式 】C40H72N2O13 【 分 子 量 】789.01736 【元素组成】C 60.89% H 9.2% N 3.55% O 26.36% |
合成路线1
该中间体在本合成路线中的序号：(III)Alkylation of silylated erythromycin oxime (I) with allyl bromide in the presence of t-BuOK provided allyl ether (II). After acid hydrolysis of the cyclo hexylidene ketal of (II), the oxime group was removed by treatment with NaHSO3 and formic acid to afford ketone (IV). Subsequent cleavage of the 3-O-cladinose unit of (IV) by hydrolysis with HCl furnished ketolide (V). The 2'-hydroxyl group of (V) was then protected by benzoylation with benzoic anhydride yielding (VI).
| 【1】 Flamm, R.K.; Raney, P.M.; Nilius, A.M.; Bui, M.; Or, Y.S.; Wang, S.; Plattner, J.J.; Ma, Z.; Clark, R.; Chu, D.T.W.; Synthesis and antibacterial activity of 6-O-substituted ketolides. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24 1998, San Diego) 1998, Abst F-126. |
| 【2】 Or, Y.S.; Ma, Z.; Clark, R.F.; Chu, D.T.; Plattner, J.J. (Abbott Laboratories Inc.); 6-O-Substd. ketolides having antibacterial activity. EP 0929563; US 5866549; WO 9809978 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 28388 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-7,12,13-trihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C54H104N2O12Si2 | 详情 | 详情 | |
| (II) | 28389 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-12,13-dihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C57H108N2O12Si2 | 详情 | 详情 | |
| (III) | 28390 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-oxime | C40H72N2O13 | 详情 | 详情 | |
| (IV) | 28391 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H71NO13 | 详情 | 详情 | |
| (V) | 28429 | (3R,4S,5S,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-4,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C32H57NO10 | 详情 | 详情 | |
| (VI) | 28430 | (2S,3R,4S,6R)-2-[[(3R,4S,5S,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-14-ethyl-4,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecanyl]oxy]-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-3-yl benzoate | C39H61NO11 | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(III)Alkylation of protected erythromycin (I) at the 6-hydroxyl group with allyl bromide provided ether (II). Hydrolysis of the cyclohexylidene ketal group of (II) with concomitant desilylation with AcOH gave (III). The oxime function was then hydrolyzed using either sodium bisulfite and formic acid or sodium nitrite and HCl to afford ketone (IV). Dihydroxylation of the allyl group of (IV) by means of N-methylmorpholine-N-oxide and a catalytic amount of OsO4, followed by oxidative cleavage of the resulting glycol (V) with NaIO4 produced aldehyde (VI). Alternatively, aldehyde (VI) was obtained by ozonolysis of the allyl ether (IV).
| 【1】 Bui, M.H.; Plattner, J.J.; Ramney, p.M.; Nilius, A.M.; Chu, D.T.W.; Or, Y.S.; Wang, S.; Clark, R.F.; Henry, R.F.; Ma, Z.; Novel 6-O-substituted erythromycin A derivatives. Synthesis and antibacterial activity. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24 1998, San Diego) 1998, Abst F-125. |
| 【2】 Wang, S.; Ma, Z.; Clark, R.F.; et al.; Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives. Bioorg Med Chem Lett 2000, 10, 8, 815. |
| 【3】 Or, Y.S.; Chu, D.T.; Clark, R.F.; Ma, Z. (Abbott Laboratories Inc.); 6-O-Substd. erythromycins and method for making them. EP 0918783; EP 1007530; JP 2000509712; US 6075011; WO 9742204; WO 9742206 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 28388 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-7,12,13-trihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C54H104N2O12Si2 | 详情 | 详情 | |
| (II) | 28389 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-12,13-dihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C57H108N2O12Si2 | 详情 | 详情 | |
| (III) | 28390 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-oxime | C40H72N2O13 | 详情 | 详情 | |
| (IV) | 28391 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H71NO13 | 详情 | 详情 | |
| (V) | 28392 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(2,3-dihydroxypropoxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H73NO15 | 详情 | 详情 | |
| (VI) | 28393 | 2-[((3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecanyl)oxy]acetaldehyde | C39H69NO14 | 详情 | 详情 |
合成路线3
该中间体在本合成路线中的序号：(III)Alkylation of protected erythromycin (I) at the 6-hydroxyl group with allyl bromide provided ether (II). Hydrolysis of the cyclohexylidene ketal group of (II) with concomitant desilylation with AcOH gave (III). The oxime function of (III) was then hydrolyzed using either sodium bisulfite and formic acid or sodium nitrite and HCl to afford ketone (IV). Dihydroxylation of the allyl group of (IV) by means of N-methylmorpholine-N-oxide and a catalytic amount of OsO4, followed by oxidative cleavage of the resulting glycol (V) with NaIO4 produced aldehyde (VI). Alternatively, aldehyde (VI) was obtained by ozonolysis of the allyl ether (IV).
| 【1】 Bui, M.H.; Plattner, J.J.; Ramney, p.M.; Nilius, A.M.; Chu, D.T.W.; Or, Y.S.; Wang, S.; Clark, R.F.; Henry, R.F.; Ma, Z.; Novel 6-O-substituted erythromycin A derivatives. Synthesis and antibacterial activity. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24 1998, San Diego) 1998, Abst F-125. |
| 【2】 Or, Y.S.; Chu, D.T.; Clark, R.F.; Ma, Z. (Abbott Laboratories Inc.); 6-O-Substd. erythromycins and method for making them. EP 0918783; EP 1007530; JP 2000509712; US 6075011; WO 9742204; WO 9742206 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 28388 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-7,12,13-trihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C54H104N2O12Si2 | 详情 | 详情 | |
| (II) | 28389 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-12,13-dihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C57H108N2O12Si2 | 详情 | 详情 | |
| (III) | 28390 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-oxime | C40H72N2O13 | 详情 | 详情 | |
| (IV) | 28391 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H71NO13 | 详情 | 详情 | |
| (V) | 28392 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(2,3-dihydroxypropoxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H73NO15 | 详情 | 详情 | |
| (VI) | 28393 | 2-[((3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecanyl)oxy]acetaldehyde | C39H69NO14 | 详情 | 详情 |
合成路线4
该中间体在本合成路线中的序号：(III)Alkylation of protected erythromycin (I) at the 6-hydroxyl group with allyl bromide provided ether (II). Hydrolysis of the cyclohexylidene ketal group of (II) with concomitant desilylation with AcOH gave (III). The oxime function of (III) was then hydrolyzed using either sodium bisulfite and formic acid or sodium nitrite and HCl to afford ketone (IV). Dihydroxylation of the allyl group of (IV) by means of N-methylmorpholine-N-oxide and a catalytic amount of OsO4, followed by oxidative cleavage of the resulting glycol (V) with NaIO4 produced aldehyde (VI). Alternatively, aldehyde (VI) was obtained by ozonolysis of the allyl ether (IV).
| 【1】 Bui, M.H.; Plattner, J.J.; Ramney, p.M.; Nilius, A.M.; Chu, D.T.W.; Or, Y.S.; Wang, S.; Clark, R.F.; Henry, R.F.; Ma, Z.; Novel 6-O-substituted erythromycin A derivatives. Synthesis and antibacterial activity. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24 1998, San Diego) 1998, Abst F-125. |
| 【2】 Wang, S.; Ma, Z.; Clark, R.F.; et al.; Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives. Bioorg Med Chem Lett 2000, 10, 8, 815. |
| 【3】 Or, Y.S.; Chu, D.T.; Clark, R.F.; Ma, Z. (Abbott Laboratories Inc.); 6-O-Substd. erythromycins and method for making them. EP 0918783; EP 1007530; JP 2000509712; US 6075011; WO 9742204; WO 9742206 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 28388 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-7,12,13-trihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C54H104N2O12Si2 | 详情 | 详情 | |
| (II) | 28389 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-12,13-dihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C57H108N2O12Si2 | 详情 | 详情 | |
| (III) | 28390 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-oxime | C40H72N2O13 | 详情 | 详情 | |
| (IV) | 28391 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H71NO13 | 详情 | 详情 | |
| (V) | 28392 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(2,3-dihydroxypropoxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H73NO15 | 详情 | 详情 | |
| (VI) | 28393 | 2-[((3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecanyl)oxy]acetaldehyde | C39H69NO14 | 详情 | 详情 |